Michael Spreadborough – Executive Co-Chairman – NOVO Resources (ASX:NVO) is a gold explorer with one of the largest prospective gold and battery metals land packages in the Pilbara, a premier exploration and mining region located in Western Australia.
Copyright 2024 – Finance News Network
20 Sep 2019 - Prospect Resources Limited (ASX:PSC) Managing Director, Sam Hosack provides an update on the company's Arcadia lithium project in Zimbabwe, including advanced negotiations with a number of African and international banks on funding.
12 Feb 2020 - Mayur Resources Limited (ASX:MRL) Managing Director, Paul Mulder provides an update on the company's PNG projects, which span industrial minerals, power generation, coal, copper and gold.
08 Aug 2023 - WT Financial Group Limited (ASX:WTL) Managing Director Keith Cullen discusses drivers of profitability, the effect of lower adviser numbers in the industry and opportunities moving forward.
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
16 Aug 2023 - Yoav Amitai - CEO - Elsight's (ASX:ELS) Halo provides connectivity and delivers absolute connection confidence for drones and other unmanned systems.
06 Jul 2023 - Tamboran Resources Limited (ASX:TBN) Managing Director and CEO Joel Riddle discusses the company's recent capital raise, the drilling timeline, and agreements with APA Group, Clean Energy Fuels Australia, BP and Shell.
29 Feb 2024 - Greg Miles - Managing Director - Caspin Resources Limited (ASX Code: CPN) is a new mineral exploration company based in Perth, Western Australia. Caspin has extensive skills and experience in early stage exploration and development. The Company is actively exploring the Yarawindah Brook Project in Australia’s exciting new PGE-Ni-Cu West Yilgarn province and the Mount Squires Project in the West Musgrave region, one of Australia’s last mineral exploration frontiers.
16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.